Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
HIP2B is being developed for the treatment of type 1 and type 2 diabetes mellitus.
The purpose of this study is to investigate the safety and tolerability of repeat doses of
HIP2B in subjects with type 2 diabetes mellitus. The study will also assess whether islet
β-cell number and function will increase over time in response to repeat HIP2B injections.